INVESTALGA AHTI S.L.

investalga.com

INVESTALGA is a Spanish innovative biotech specializing in the production of high quality bioactive compounds from green seaweeds available for use in nutrition, personal care and health markets. We are developing a scientific-technical-industrial base combining various disciplines: biotechnology, marine ecology, aquaculture, chemistry, nutrition and medicine, to credit and put value to the numerous possibilities derived from the unique biochemical composition of green seaweeds.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

ENVERIC BIOSCIENCES ADVANCES DRUG DEVELOPMENT FOR MENTAL HEALTH INDICATIONS AND INTELLECTUAL PROPERTY PORTFOLIO

Enveric Biosciences, Inc | July 14, 2022

news image

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy Psy...

Read More

MedTech, Industrial Impact

TWIST BIOSCIENCE ANNOUNCES TECHNOLOGY EARLY ACCESS OF EWGS SOLUTION

Twist Bioscience Corporation | February 13, 2023

news image

Twist Bioscience Corporation, a company that helps customers succeed by providing high-quality synthetic DNA on its silicon platform, recently announced technology early access to the Twist enhanced Whole Genome Sequencing (eWGS) solution for applications related to non-human gnomics at the Advances in Genome Biology and Technology 2023 General Meeting conducted in Hollywood, Florida. eWGS is a unique solution that allows researchers to collect simultaneous low-pass whole genome data as we...

Read More

Cell and Gene Therapy

MUSC AND HELIX LAUNCH IN OUR DNA SC, FIRST-OF-ITS-KIND POPULATION GENOMICS PROGRAM TO DRIVE PREVENTIVE, PRECISION HEALTH CARE FOR SOUTH CAROLINIANS

Helix | September 21, 2021

news image

The Medical University of South Carolina (MUSC) and Helix have announced a strategic collaboration to develop a first-of-its-kind population genomics initiative in South Carolina called In Our DNA SC. The large-scale program is designed to improve health care outcomes by integrating genetic insights into clinical care and research. The statewide initiative will enroll 100,000 patients in genetic testing over the next four years at no cost to the patient. The program will enable th...

Read More

Industrial Impact

MERAKRIS AND DEPT. OF VETERANS AFFAIRS SIGN CRADA AGREEMENT – CLINICAL TRIAL FOR DERMACYTE® WOUND CARE PRODUCT TO BEGIN SOON

Merakris Therapeutics | February 09, 2022

news image

Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to test its investigational drug product, Dermacyte® Amniotic Wound Care Liquid. The VA plans to enroll patients, ages 18-75, in a two-part Phase II clinical study to evaluate Merakris’ first in class subcutaneous – or below the skin – injectable wound healing therapy. The study is designe...

Read More
news image

Industrial Impact

ENVERIC BIOSCIENCES ADVANCES DRUG DEVELOPMENT FOR MENTAL HEALTH INDICATIONS AND INTELLECTUAL PROPERTY PORTFOLIO

Enveric Biosciences, Inc | July 14, 2022

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy Psy...

Read More
news image

MedTech, Industrial Impact

TWIST BIOSCIENCE ANNOUNCES TECHNOLOGY EARLY ACCESS OF EWGS SOLUTION

Twist Bioscience Corporation | February 13, 2023

Twist Bioscience Corporation, a company that helps customers succeed by providing high-quality synthetic DNA on its silicon platform, recently announced technology early access to the Twist enhanced Whole Genome Sequencing (eWGS) solution for applications related to non-human gnomics at the Advances in Genome Biology and Technology 2023 General Meeting conducted in Hollywood, Florida. eWGS is a unique solution that allows researchers to collect simultaneous low-pass whole genome data as we...

Read More
news image

Cell and Gene Therapy

MUSC AND HELIX LAUNCH IN OUR DNA SC, FIRST-OF-ITS-KIND POPULATION GENOMICS PROGRAM TO DRIVE PREVENTIVE, PRECISION HEALTH CARE FOR SOUTH CAROLINIANS

Helix | September 21, 2021

The Medical University of South Carolina (MUSC) and Helix have announced a strategic collaboration to develop a first-of-its-kind population genomics initiative in South Carolina called In Our DNA SC. The large-scale program is designed to improve health care outcomes by integrating genetic insights into clinical care and research. The statewide initiative will enroll 100,000 patients in genetic testing over the next four years at no cost to the patient. The program will enable th...

Read More
news image

Industrial Impact

MERAKRIS AND DEPT. OF VETERANS AFFAIRS SIGN CRADA AGREEMENT – CLINICAL TRIAL FOR DERMACYTE® WOUND CARE PRODUCT TO BEGIN SOON

Merakris Therapeutics | February 09, 2022

Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to test its investigational drug product, Dermacyte® Amniotic Wound Care Liquid. The VA plans to enroll patients, ages 18-75, in a two-part Phase II clinical study to evaluate Merakris’ first in class subcutaneous – or below the skin – injectable wound healing therapy. The study is designe...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us